Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.

Kierzek AM, Hickling TP, Figueroa I, Kalvass JC, Nijsen M, Mohan K, Veldman GM, Yamada A, Sayama H, Yokoo S, Gulati A, Dhanikula RS, Gokemeijer J, Leil TA, Thalhauser CJ, Giorgi M, Swat MJ, Chelliah V, Small BG, Benson N, Walker M, Gadkar K, Quarmby V, Deng R, Ferrante A, Dickinson GL, Van Der Walt JS, Zhou L, Chen X, Jones HM, Narula J, Tourdot S, Lavé T, Ribba B, van der Graaf PH.

CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):773-776. doi: 10.1002/psp4.12465. Epub 2019 Oct 8. No abstract available.

2.

Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies.

Zhang TT, Ma J, Durbin KR, Montavon T, Lacy SE, Jenkins GJ, Doktor S, Kalvass JC.

AAPS J. 2019 Jun 27;21(5):82. doi: 10.1208/s12248-019-0352-8.

PMID:
31250228
3.

Mathematical and Experimental Validation of Flux Dialysis Method: An Improved Approach to Measure Unbound Fraction for Compounds with High Protein Binding and Other Challenging Properties.

Kalvass JC, Phipps C, Jenkins GJ, Stuart P, Zhang X, Heinle L, Nijsen MJMA, Fischer V.

Drug Metab Dispos. 2018 Apr;46(4):458-469. doi: 10.1124/dmd.117.078915. Epub 2018 Feb 2.

PMID:
29437872
4.

Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs.

Di L, Breen C, Chambers R, Eckley ST, Fricke R, Ghosh A, Harradine P, Kalvass JC, Ho S, Lee CA, Marathe P, Perkins EJ, Qian M, Tse S, Yan Z, Zamek-Gliszczynski MJ.

J Pharm Sci. 2017 Dec;106(12):3442-3452. doi: 10.1016/j.xphs.2017.09.005. Epub 2017 Sep 18. Review.

PMID:
28927987
5.

ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.

Lee CA, Kalvass JC, Galetin A, Zamek-Gliszczynski MJ.

Clin Pharmacol Ther. 2014 Sep;96(3):298-301. doi: 10.1038/clpt.2014.94.

PMID:
25141954
6.

In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class.

Kikuchi R, de Morais SM, Kalvass JC.

Drug Metab Dispos. 2013 Dec;41(12):2012-7. doi: 10.1124/dmd.113.053868. Epub 2013 Sep 5. Review.

PMID:
24009309
7.

ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25. Review.

8.

Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.

Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, Zamek-Gliszczynski MJ; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):80-94. doi: 10.1038/clpt.2013.34. Epub 2013 Feb 14. Review.

PMID:
23588303
9.

Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.

Zhao R, Kalvass JC, Pollack GM.

Pharm Res. 2009 Jul;26(7):1657-64. doi: 10.1007/s11095-009-9876-4. Epub 2009 Apr 22.

PMID:
19384470
10.

Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration.

Zhao R, Kalvass JC, Yanni SB, Bridges AS, Pollack GM.

Drug Metab Dispos. 2009 Mar;37(3):529-35. doi: 10.1124/dmd.107.019893. Epub 2008 Dec 29.

11.

Relationship between drug/metabolite exposure and impairment of excretory transport function.

Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL.

Drug Metab Dispos. 2009 Feb;37(2):386-90. doi: 10.1124/dmd.108.023648. Epub 2008 Nov 20.

12.

Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats.

Kielbasa W, Kalvass JC, Stratford R.

Drug Metab Dispos. 2009 Jan;37(1):137-42. doi: 10.1124/dmd.108.023119. Epub 2008 Oct 20.

PMID:
18936112
13.

Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data.

Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM.

J Pharmacol Exp Ther. 2007 Oct;323(1):346-55. Epub 2007 Jul 23.

PMID:
17646430
17.

The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.

Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, Brouwer KL.

Mol Pharmacol. 2006 Dec;70(6):2127-33. Epub 2006 Sep 7.

PMID:
16959944
18.

In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation.

Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS.

Mol Pharmacol. 2006 Oct;70(4):1212-9. Epub 2006 Jul 12.

PMID:
16837625
19.

Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.

Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KL.

J Pharmacol Exp Ther. 2006 Aug;318(2):881-9. Epub 2006 May 11.

PMID:
16690724
20.

Comment: Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets.

Kalvass JC, Phinney SD, Vernon MC, Rosedale R, Westman EC.

Ann Pharmacother. 2005 Jul-Aug;39(7-8):1371-2; author reply 1372. Epub 2005 May 31. No abstract available.

PMID:
15928257
21.

Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.

Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, Brouwer KL.

Drug Metab Dispos. 2005 Aug;33(8):1158-65. Epub 2005 Apr 28.

PMID:
15860656
22.

Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.

Kalvass JC, Graff CL, Pollack GM.

Pharm Res. 2004 Oct;21(10):1867-70.

PMID:
15553234
23.

In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist.

Elliott RL, Oliver RM, Hammond M, Patterson TA, She L, Hargrove DM, Martin KA, Maurer TS, Kalvass JC, Morgan BP, DaSilva-Jardine PA, Stevenson RW, Mack CM, Cassella JV.

J Med Chem. 2003 Feb 27;46(5):670-3.

PMID:
12593645
24.
25.

Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data.

Kalvass JC, Tess DA, Giragossian C, Linhares MC, Maurer TS.

Drug Metab Dispos. 2001 Oct;29(10):1332-6.

PMID:
11560877
26.

L-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibers in the spleens of old F344 rats.

ThyagaRajan S, Madden KS, Kalvass JC, Dimitrova SS, Felten SY, Felten DL.

J Neuroimmunol. 1998 Dec 1;92(1-2):9-21.

PMID:
9916875

Supplemental Content

Loading ...
Support Center